BioAI, a biotech company specializing in AI-driven biomarker discovery, has announced a strategic partnership with Arbele, a biopharmaceutical firm focusing on immunotherapies for gastrointestinal cancers. The partnership aims to leverage BioAI’s PredictX platform using Arbele’s clinical trial data to advance AI-based colorectal cancer (CRC) diagnostics.
- Focus of the Collaboration
BioAI and Arbele will develop AI models to analyze colorectal cancer biomarkers, specifically aiming to create a companion diagnostic test for Arbele’s therapeutic assets. This will enable more accurate patient selection for immunotherapeutic treatments. - PredictX AI Platform
BioAI’s PredictX platform applies multimodal AI to identify biomarkers, enhance diagnostics, and improve personalized treatment strategies. By analyzing H&E (hematoxylin and eosin) and IHC (immunohistochemistry) images, the AI will quantify CDH17 expression patterns, providing actionable insights for CRC therapy. - Strategic Goals
The collaboration’s primary goal is to standardize the pathologic assessment of treatment response biomarkers. This will facilitate better patient stratification for Arbele’s clinical trials and improve outcomes for CRC patients.
Leadership Statements:
- Thomas Colarusso, CEO of BioAI
“This partnership with Arbele represents a breakthrough in applying AI to improve cancer diagnostics and treatment. Our PredictX platform will accelerate the development of innovative therapeutic options for gastrointestinal cancers.” - Dr. John Luk, CEO & Founder of Arbele
“BioAI’s expertise in AI-driven biomarker identification aligns perfectly with our mission to develop transformative immunotherapies. Together, we will enhance patient selection and treatment outcomes for high-mortality cancers like colorectal cancer.”
Phase One Development:
- Machine Learning Classifier Model
The initial phase will focus on building a machine learning classifier model to detect and quantify CDH17 expression in CRC samples. This model will be developed using a combination of H&E and IHC-stained images, ensuring that pathologic assessments are more standardized and precise. - Precision Medicine
The collaboration underscores a shared commitment to advancing precision medicine. By integrating AI into biomarker discovery, BioAI and Arbele aim to bring new levels of accuracy and efficiency to cancer diagnostics, ultimately benefiting patients with gastrointestinal cancers.
The partnership between BioAI and Arbele is a significant step toward revolutionizing cancer diagnostics and treatment. Through AI-based biomarker discovery and precise patient selection, the collaboration will pave the way for improved therapeutic outcomes in colorectal and other gastrointestinal cancers.
